ImmuPharma PLC (AIM:IMM) shares surged 19% in early trading on Thursday after CEO Tim McCarthy hailed "stunning results" from a breakthrough study on its lead drug, P140.
The findings confirm that P140 has a unique mechanism of action and, crucially, does not suppress the immune system—setting it apart from many existing autoimmune treatments. Unlike other drugs that weaken the body's defences, P140 allows a targeted immune response while remaining effective and safe.
The study was conducted in a leading US laboratory, with full data to be released later. ImmuPharma says the results will strengthen its intellectual property portfolio, leading to new patents and boosting commercial potential.
The autoimmune therapy market is forecast to hit $360 billion in global sales by 2030, making P140 an attractive licensing prospect.
McCarthy said the findings would be key in talks with potential partners. Sébastien Goudreau, boss of the ImmuPharma Biotech arm of the business, added that the results could put P140 at the heart of autoimmune disease treatment.
The shares were up 0.64p at 4p.